We read with great interest the recent article by Trifilio et al 1 reporting their experience with correlating voriconazole levels with biological parameters and the variability of these levels. This is by no means a new concern in fact, Potoski and Brown 2 reported their concerns about the very same topic several years ago when voriconazole was initially approved by the US FDA. Our issues with this article are mainly related to the authors advocating the use of routine therapeutic drug monitoring when toxic and therapeutic ranges have not yet been established for this agent. Furthermore, the authors established their own therapeutic range for voriconazole (ie, 0.5-7 mg/ml) without providing any rationale or references.
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The rationale for therapeutic drug monitoring (TDM) is to incorporate drug concentrations, pharmacokinetics and pharmacodynamics to optimize drug therapy for individual patients. 3 In order to achieve this optimization, one must have a solid understanding of the therapeutic and toxic ranges of the agent in question. Little information is available in the way of identifying optimal plasma concentrations for voriconazole. Denning and colleagues have postulated that plasma concentrations of voriconazole 4250 ng/ml are consistent with the threshold of response to invasive aspergillosis. 4 Trifilio and colleagues used 500 ng/ml as their accepted lower threshold. It appears that this threshold may have been derived from two in vitro studies. However, after reviewing these studies, we are still unclear how the authors arrived at the 500 ng/ml value. 5, 6 Furthermore, as with other triazoles, the AUC/MIC ratio is the pharmacodynamic parameter that correlates best with efficacy. 7 The use of one plasma level as a means to interpret AUC/MIC is grossly insufficient. Since voriconazole has nonlinear pharmacokinetics at therapeutic dosages, reduced bioavailability when taken with food, and considerable interpatient variability in hepatic metabolism, correlating its pharmacokinetics to efficacy in patients will be a formidable challenge.
This can also be said for toxic voriconazole levels. Investigations have not identified a threshold plasma concentration above which the risk of abnormal LFT results was increased when compared with lower plasma concentrations. Moreover, it is unclear in this analysis whether the abnormal LFTs resulted from previous chemotherapy or from voriconazole administration, or if the higher voriconazole levels were a result of chemotherapy-induced hepatic toxicity. Instead of advocating the widespread use of voriconazole plasma levels for which we have no interpretive criteria, perhaps a better message would be to argue in support of research to identify the toxic and therapeutic range for this agent. The authors only briefly suggest that well controlled studies are needed to further address the question of voriconazole TDM, which in our opinion is a tremendous understatement. It is also striking that the investigators reported obtaining five plasma levels from one patient. Based on their account, three of these levels were done because this particular patient developed chronic renal failure. What impact does renal failure have on oral voriconazole? Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose being exceeded in the urine. 8 Lastly, is the issue of expense based on local-information each level obtained cost the institution $175. For the above-mentioned patients, these five levels cost the institution $875. Perhaps these funds are better allocated elsewhere given the lack of therapeutic benefit of voriconazole TDM. 
